Thorens

How to order Thorens

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Thorens on Prescriptsy

Thorens is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Thorens is a generic tiotropium bromide inhaler licensed in the United Kingdom for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Tiotropium is a long-acting muscarinic antagonist (LAMA) that provides sustained 24-hour bronchodilation with once-daily dosing.

It is one of the most widely prescribed maintenance bronchodilators for COPD worldwide and is recommended as a first-line long-acting inhaler by both NICE and the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

COPD is a major cause of morbidity and mortality in the United Kingdom, affecting an estimated 1.2 million people with a confirmed diagnosis and a further 2 million believed to be undiagnosed.

It is the second most common reason for emergency hospital admission in the UK and the fifth leading cause of death.

This page provides comprehensive clinical information about Thorens, including how tiotropium works, dosing guidance, potential side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Thorens

Before reading further, note the following key safety points about Thorens.

• Thorens is a maintenance inhaler. It must not be used as a rescue inhaler for sudden breathlessness. Always carry a separate short-acting bronchodilator for acute symptoms.
• Avoid getting the inhaled medication into your eyes. Anticholinergic drugs can precipitate or worsen narrow-angle glaucoma.
• If you have an enlarged prostate or bladder problems, use Thorens with caution and report any urinary difficulty immediately.
• Use Thorens every day at the same time, even when you feel well. Do not stop without medical advice.

What is COPD

Chronic obstructive pulmonary disease (COPD) is a progressive, largely irreversible lung condition characterised by persistent airflow limitation.

It encompasses two main pathological processes: chronic bronchitis (inflammation and excess mucus production in the bronchial tubes) and emphysema (destruction of the alveolar walls, reducing the surface area for gas exchange).

Most patients have elements of both. The primary cause of COPD in the UK is cigarette smoking, which accounts for approximately 80 to 90% of cases.

Other risk factors include occupational dust and chemical exposure, indoor air pollution (biomass fuel use), alpha-1 antitrypsin deficiency, and a history of childhood respiratory infections.

COPD typically presents after the age of 35 with gradually progressive breathlessness on exertion, chronic cough, and sputum production.

As the disease advances, breathlessness limits daily activities, and patients become susceptible to acute exacerbations triggered by respiratory infections, air pollution, or temperature changes.

Exacerbations accelerate lung function decline, reduce quality of life, and carry a significant mortality risk, particularly when they require hospitalisation.

COPD in the United Kingdom

According to the British Lung Foundation (now Asthma + Lung UK), COPD is the second most common lung disease in the UK after asthma.

It is estimated to cost the NHS more than 1.9 billion pounds annually through direct healthcare costs and is responsible for approximately 30,000 deaths per year.

COPD disproportionately affects people in socioeconomically deprived areas, reflecting the higher prevalence of smoking and occupational exposures in these populations.

NICE Guideline NG115 and the GOLD report provide comprehensive frameworks for the diagnosis, assessment, and management of COPD in the UK.

How Thorens works: mechanism of action

Tiotropium bromide is a long-acting anticholinergic bronchodilator that works by blocking muscarinic receptors (specifically M3 receptors) on airway smooth muscle cells.

In COPD, cholinergic tone (mediated by the vagus nerve releasing acetylcholine) is the primary reversible component of airflow obstruction.

Acetylcholine binds to M3 receptors on bronchial smooth muscle, causing contraction and narrowing of the airways. Tiotropium blocks this interaction, allowing the airways to relax and dilate.

The key pharmacological advantage of tiotropium over short-acting anticholinergics (such as ipratropium) is its exceptionally slow dissociation from M3 receptors.

While ipratropium dissociates from M3 receptors within minutes, tiotropium remains bound for approximately 35 hours. This kinetic selectivity underpins the sustained 24-hour bronchodilatory effect achieved with once-daily dosing.

Tiotropium dissociates more rapidly from M2 receptors (which have a feedback function in the parasympathetic nervous system), resulting in a degree of kinetic selectivity for M3 over M2 receptors in clinical use.

Beyond bronchodilation, tiotropium reduces mucus hypersecretion by blocking M3 receptors on submucosal glands.

It also reduces air trapping and dynamic hyperinflation, two hallmarks of COPD that contribute significantly to exertional breathlessness.

By reducing resting lung volumes (residual volume and functional residual capacity), tiotropium allows patients to breathe more efficiently during exercise, improving exercise tolerance and reducing the sensation of dyspnoea.

Clinical evidence and national guidelines

Tiotropium is one of the most extensively studied bronchodilators in COPD.

The landmark UPLIFT trial (Understanding Potential Long-term Impacts on Function with Tiotropium) was a 4-year, randomised, double-blind, placebo-controlled trial involving 5,993 patients with moderate to very severe COPD.

Tiotropium significantly improved lung function (FEV1), reduced exacerbation rates, improved quality of life scores (measured by the St George's Respiratory Questionnaire), and was associated with a trend towards reduced mortality, although this did not reach statistical significance.

The safety profile was favourable, with no increase in cardiovascular events compared with placebo.

The POET-COPD trial compared tiotropium with salmeterol (a LABA) and found that tiotropium was superior in reducing COPD exacerbations, with a 17% reduction in the time to first exacerbation compared with salmeterol.

This finding supports the position of LAMAs as preferred first-line long-acting bronchodilators in COPD patients at risk of exacerbations.

NICE Guideline NG115 (Chronic obstructive pulmonary disease in over 16s: diagnosis and management) recommends offering a LAMA (such as tiotropium) as initial maintenance therapy for patients with COPD who remain breathless or have exacerbations despite short-acting bronchodilator use.

For patients with persistent symptoms or frequent exacerbations on LAMA monotherapy, dual bronchodilation with LAMA plus LABA, or triple therapy with LAMA plus LABA plus ICS, may be appropriate.

The GOLD 2024 report similarly positions LAMA monotherapy as a first-line option in Group A and Group B COPD patients.

Dosage and administration

Thorens is administered as one inhalation once daily. The exact dose depends on the specific inhaler device.

Patients should be trained in the correct use of their device by a pharmacist, practice nurse, or respiratory clinician before starting treatment, and technique should be reviewed at each COPD review appointment.

General inhalation instructions

Remove the dose from the device according to the manufacturer's instructions. Breathe out gently and fully, away from the device.

Place the mouthpiece between the lips, forming a tight seal. Breathe in slowly, steadily, and deeply through the mouth.

Remove the device and hold the breath for approximately 10 seconds before exhaling slowly. Do not exhale into the device.

If throat irritation occurs after inhalation, rinsing the mouth with water may help.

Missed doses

If a dose is missed, take it as soon as remembered unless it is close to the time for the next dose.

Do not inhale two doses at the same time or within a few hours of each other, as this increases the risk of anticholinergic side effects including dry mouth, urinary retention, and tachycardia.

Side effects of Thorens

Common side effects

Dry mouth is the most frequently reported adverse effect of tiotropium, occurring in approximately 4 to 16% of patients across clinical trials.

It results from muscarinic receptor blockade on salivary glands. Most patients find it mild and manageable with regular fluid intake and sugar-free chewing gum.

Persistent dry mouth can increase the risk of dental caries and oral infections, so maintaining good dental hygiene and attending regular dental appointments is important.

Anticholinergic effects

Other anticholinergic side effects include constipation (1 to 3%), urinary hesitancy, and, in susceptible patients (particularly men with prostatic hypertrophy), urinary retention.

Patients who develop difficulty passing urine should stop Thorens and seek medical advice immediately, as acute urinary retention requires urgent catheterisation.

Respiratory and local effects

Pharyngitis, sinusitis, cough, and throat irritation are reported.

Paradoxical bronchospasm (sudden worsening of wheeze and breathlessness immediately after inhalation) is rare but requires immediate use of a reliever inhaler, cessation of Thorens, and medical review.

Upper respiratory tract infections are reported more frequently in tiotropium users, although this may partly reflect the natural history of COPD rather than a direct drug effect.

Cardiovascular effects

Tachycardia and palpitations are uncommon. Atrial fibrillation and other supraventricular tachyarrhythmias have been reported in post-marketing surveillance.

The UPLIFT trial, however, did not demonstrate an increased risk of major adverse cardiovascular events, stroke, or cardiovascular death with tiotropium over 4 years.

Patients with pre-existing cardiac arrhythmias should be monitored.

Ocular effects

If tiotropium inadvertently contacts the eyes, it can cause pupil dilation, blurred vision, and in predisposed individuals, acute angle-closure glaucoma.

Patients should be instructed to avoid directing the inhaler towards the eyes. Symptoms of acute angle-closure glaucoma include sudden severe eye pain, visual halos, nausea, and red eye.

This is a medical emergency requiring immediate ophthalmological assessment.

Warnings and precautions

Not a rescue inhaler

Thorens is designed for regular daily maintenance use and does not provide rapid bronchodilation for acute symptoms.

All COPD patients using Thorens must also have access to a short-acting bronchodilator inhaler for use during acute exacerbations or sudden worsening of breathlessness.

If reliever inhaler use increases or becomes insufficient, seek urgent medical advice.

Narrow-angle glaucoma

Patients with known or suspected narrow-angle glaucoma should use Thorens with caution. Anticholinergic drugs can trigger an acute glaucoma attack in predisposed individuals. If visual symptoms develop after starting Thorens, seek immediate medical assessment.

Prostatic hyperplasia and bladder obstruction

Tiotropium should be used with caution in men with benign prostatic hyperplasia or bladder neck obstruction. Anticholinergic effects can worsen urinary outflow obstruction and precipitate acute urinary retention. Patients should be advised to report any changes in urinary pattern promptly.

Renal impairment

Tiotropium is excreted predominantly by the kidneys.

In patients with moderate to severe renal impairment (creatinine clearance below 50 ml per minute), plasma concentrations of tiotropium may be elevated, increasing the potential for anticholinergic side effects.

Close monitoring is recommended in these patients.

Pregnancy and breastfeeding

There are limited data on the use of tiotropium in pregnant women.

Animal studies have not demonstrated teratogenic effects, but tiotropium should be used during pregnancy only if the expected benefit to the mother outweighs any potential risk to the foetus.

It is not known whether tiotropium is excreted in human breast milk.

A decision should be made whether to discontinue breastfeeding or discontinue therapy, taking into account the benefit of breastfeeding to the child and the benefit of therapy to the mother.

How to get a Thorens prescription in the UK

Thorens is a prescription-only medicine (POM) in the UK.

It is typically prescribed following a confirmed diagnosis of COPD, which requires spirometry demonstrating a post-bronchodilator FEV1/FVC ratio of less than 0.70 in the context of appropriate symptoms and risk factor exposure.

Your GP, practice nurse, or respiratory specialist will assess your symptoms, measure your lung function, and determine the most appropriate inhaler regimen based on NICE NG115 guidance.

Repeat prescriptions can be arranged through your GP surgery or through authorised online prescribers registered with the GPhC. All UK prescriptions are dispensed by registered pharmacies.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Patients with COPD in England may be eligible for a prescription prepayment certificate (PPC), which can save money if they require multiple prescription items each month.

Living with COPD: practical management

Using Thorens regularly every day is a key part of managing COPD, but effective management also includes several complementary strategies.

Stopping smoking is the single most important intervention in COPD and the only measure proven to slow the rate of lung function decline.

The NHS offers free stop smoking services including behavioural support and pharmacotherapy (nicotine replacement, varenicline, bupropion).

Pulmonary rehabilitation, a structured programme of exercise and education, is recommended by NICE for all COPD patients who are functionally limited by breathlessness.

It has been shown to improve exercise capacity, reduce breathlessness, and improve quality of life.

Annual influenza vaccination and pneumococcal vaccination are recommended for all COPD patients to reduce the risk of infective exacerbations.

Patients should have a written COPD self-management plan agreed with their clinical team, detailing how to recognise the early signs of an exacerbation and when to start rescue medication (antibiotics and/or oral corticosteroids) kept at home.

Regular COPD reviews (at least annually) ensure treatment remains optimised and inhaler technique is correct.

When to seek urgent medical advice

Contact your GP or call NHS 111 if your COPD symptoms are gradually worsening, your reliever inhaler is less effective than usual, or you notice increased sputum production or a change in sputum colour.

Call 999 or attend A&E if you experience severe breathlessness at rest, are unable to speak in full sentences, have bluish discolouration of the lips or fingertips (cyanosis), feel confused or drowsy, or are not responding to your reliever inhaler.

Report any suspected adverse reactions to Thorens via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Tiotropium bromide, Summary of Product Characteristics (EMC)
• Tiotropium, British National Formulary (BNF)
• NICE NG115: Chronic obstructive pulmonary disease in over 16s
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)
• COPD, NHS
• MHRA Yellow Card Scheme